ProMab Biotechnologies, Inc.

PM-CAR1016 VEGFR-2 SCFV-CD28-CD3ζ

Ready-to use-CAR-T cells



Promab Biotechnologies' CAR-T new product development programs are being designed for pre-clinical and future clinical applications.

CAR-T cells can be used for:

1. Compound screening
2. Antibody screening
3. Co-stimulatory and activation domain comparison
4. Personalized medicine and donor variations for CAR-T screening
5. Checkpoint inhibitors
6. Safety switches and regulators of CAR-T functions
7. Pre-clinical in vivo models
8. Treg and T memory cells in CAR-T setting
9. CAR-T signaling, tumor microenvironment
10. Proof of concept studies for clinical trials

The structure of CAR from Promab's available CAR-T cells targeting VEGFR-2 antigen

VEGFR-2 (vascular endothelial growth factor receptor) can be used as a tumor antigen for targeting by CAR-T cells. VEGFR-2 has been the focus of the most research as it is the major signal transducer of angiogenesis, especially in cancerous tumors. VEGFR-2 was shown to be overexpressed in different types of tumors.



Figure 1. CAR-T cells expressing the above constructs are available from Promab targeting VEGFR-2 antigen. ScFv, single chain variable fragment. These CAR-T cells are generated with VEGFR-2 ScFv-CD28-CD3ζ CAR construct.

To date Promab generated 2nd or 3rd generation CAR and CAR controls (2nd generation of CAR is shown in Figure 1), CAR-T cells and CAR-Natural Killer (NK) effector cells against cancer target cells that show excellent functionality, including dose-dependent and target cell- specific cytotoxic activity (Figure 2).

ProMab Biotechnologies, Inc. | 2600 Hilltop Drive, Building B, Suite C320, Richmond, CA 94806 USA
Toll free 1-866-339-0871 | 1-510-860-4615 (Sales) | 1-510-860-4614 (Technical Support) | Fax 1-510-740-3625 | info@ProMab.com | www.ProMab.com

ProMab Biotechnologies, Inc.

PM-CAR1016 VEGFR-2 SCFV-CD28-CDζ

Ready-to use-CAR-T cells



These cells can be tested with CAR-T in cytotoxic assays and used for testing modulators of immune checkpoint inhibitors (PD-1, CTLA-4 pathways) or activators of immune response, small molecules affecting T cell or Treg activity.

Data



Figure 2. Real-time cytotoxic activity of VEGFR-2 ScFv-CAR-T effector cells against VEGFR-2-positive target cells. The ratio of effector cells to target cells is 10:1.

ProMab Biotechnologies, Inc. | 2600 Hilltop Drive, Building B, Suite C320, Richmond, CA 94806 USA
Toll free 1-866-339-0871 | 1-510-860-4615 (Sales) | 1-510-860-4614 (Technical Support) | Fax 1-510-740-3625 | info@ProMab.com | www.ProMab.com